Table I.
Unmatched baseline characteristics and outcomes
| Characteristics | Before propensity matching |
P value | |
|---|---|---|---|
| TNFi plus MTX (n = 214) | No TNFi or MTX (n = 31,862) | ||
| Demographics | |||
| Age at index, y ± SD | 55.1 ± 15.8 | 53.2 ± 18.9 | .1540 |
| Female, n (%) | 142 (66.4) | 17,393 (54.6) | .0006 |
| White, n (%) | 91 (42.5) | 10,958 (34.4) | .0126 |
| Comorbidities, n (%) | |||
| Diseases of the digestive system | 106 (49.5) | 5537 (17.4) | <.0001 |
| Diseases of the musculoskeletal system and connective tissue | 143 (66.8) | 6366 (20.0) | <.0001 |
| Diseases of the nervous system | 94 (43.9) | 5247 (16.5) | <.0001 |
| Diseases of the blood and blood-forming organs | 88 (41.1) | 4037 (12.7) | <.0001 |
| Diseases of the circulatory system | 131 (61.2) | 9526 (29.9) | <.0001 |
| Diseases of the skin and subcutaneous tissue | 59 (27.6) | 2307 (7.2) | <.0001 |
| Diabetes mellitus | 44 (20.6) | 3992 (12.5) | .0004 |
| Body mass index 30-39.9 kg/m2 | 40 (18.7) | 2909 (9.1) | <.0001 |
| 45-day outcomes, n (%) | |||
| Hospitalization | 61 (28.5) | 6325 (19.9) | .0016 |
| Death | 13 (6.1) | 1963 (6.2) | .9583 |
MTX, Methotrexate; SD, standard deviation; TNFi, tumor necrosis factor inhibitor.